WHAT DOES ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) MEAN?

The current work examined the potential of using ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in each p53 wild-form (WT) breast tumor cells As well as in cells missing useful p53 possibly by itself or in combination with tamoxifen, whilst the effectiveness of ABBV-744 wa